LGVN News and Press, Longeveron Inc. From 05/12/23

2023-05-12 08:21:46 ET Longeveron press release ( NASDAQ: LGVN ): Q1 GAAP EPS of -$0.22. Revenue of $0.28M (-24.3% Y/Y). For further details see: Longeveron GAAP EPS of -$0.22, revenue of $0.28M

-- New long-term survival data disclosed from ELPIS I trial of Lomecel-B TM for Hypoplastic Left Heart Syndrome; Data reinforce potential mortality benefit -- -- First patient dosed in Phase 2 clinical trial of Lomecel-B TM for Aging-Related Frailty in Japan -- ...

2023-05-10 08:38:59 ET Babylon Holdings Limited BBLN -46% . after Q1 earning release . SeaStar Medical Holding Corporation ( ICU ) -28% provides regulatory update related to its HDE application for pediatric selective cytopheretic device . Shengfeng Development...

2023-05-09 10:00:33 ET Gainers: TScan Therapeutics ( TCRX ) +151% . Ensysce Biosciences ( ENSC ) +60% . Novavax ( NVAX ) +36% . Y-mAbs Therapeutics ( YMAB ) +30% . Longeveron ( LGVN ) +26% . Losers: Enanta Pharmaceuti...

2023-05-09 09:26:21 ET Clinical-stage biotech Longeveron ( NASDAQ: LGVN ) added ~15% pre-market Tuesday after announcing long-term survival data for patients who were part of the company’s ELPIS I trial for Lomecel-B in hypoplastic left heart syndrome, (HLHS). Accordi...

- Children in the ELPIS I trial had 100% survival up to 5 years of age after receiving Lomecel-B TM compared to 20% mortality rate observed from historical control data - - Data reinforce potential survival benefit of Lomecel-B TM for patients with hypoplasti...

MIAMI, May 08, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the Company will release its first quarter 2023 financial results on Friday, M...

-- The study’s primary objective is to evaluate the safety of Lomecel-B™ in Japan’s elderly population -- -- First-in-human clinical trial of Lomecel-B™ in Japan -- -- Study will also assess efficacy endpoints expanding Longeveron’s datab...

2023-04-10 16:47:39 ET Longeveron ( NASDAQ: LGVN ) disclosed in an SEC filing Monday that on April 4, chief financial officer James Clavijo provided notice to the company of his intention to resign, effective June 9, 2023. SEC Filing . For further details see: Lo...

2023-03-10 18:40:04 ET Longeveron Inc. (LGVN) Q4 2022 Results Conference Call March 10, 2023 08:30 AM ET Company Participants James Clavijo - CFO Wa’el Hashad - CEO Dr. Chris Min - Chief Medical Officer Conference Call Participants Michael Okun...